FindTrial
Sign In

Role of empirical antibiotics for asymptomatic leukocytosis in palliative care

Role of empirical antibiotics for asymptomatic leukocytosis in non-haematological malignancy patients admitted to the palliative care ward at a tertiary care centre – an ambispective observational study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/03/050405
Enrollment
300
Registered
2023-03-06
Start date
Unknown
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C800- Disseminated malignant neoplasm, unspecified

Interventions

None listed

Sponsors

AIIMS NEW DELHI
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Non hematological malignancy with raised TLC >12,000/mm³. 2. ECOG-PS:0-4 3. Age:18 years and above 4. Patient received broad-spectrum antibiotics for increased TLC

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
To monitor changes in Total Leucocyte Count (TLC) after initiation of empirical antibiotics in non-haematological malignancy patients with a baseline leucocytosis (TLC12,000/mm³) but without clinical signs of infection.Timepoint: for prospective data- at day 1, day 3, day 5, and day 7 for retrospective data - data available from day 0 to day 7 with interval of atleast 24 hours—

Secondary

MeasureTime frame
1. Incidence of unexplained leucocytosis (Paraneoplastic Leukemoid Reaction) in patients receiving palliative care. 2. To analyse the general well-being with antibiotics in these patients with FACT-G version 4. Timepoint: at baseline and day 8—

Countries

India

Contacts

Public ContactDr Prashant sirohiya

NCI, Jhajjar, AIIMS, new delhi

sirohiyaprashant@gmail.com8824090277

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026